Works matching IS 25738348 AND DT 2022 AND VI 5 AND IP 2

Results: 19

The cost, survival, and quality-of-life implications of guideline-discordant imaging for prostate cancer.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1468

By:

Winn, Aaron N.;
Kelly, Matthew;
Ciprut, Shannon;
Walter, Dawn;
Gold, Heather T.;
Zeliadt, Steven B.;
Sherman, Scott E.;
Makarov, Danil V.

Publication type:

Article

Cross-sectional study of psychosocial well-being among lesbian, gay, bisexual, and heterosexual gynecologic cancer survivors.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1461

By:

Schefter, Alexandra;
Thomaier, Lauren;
Jewett, Patricia;
Brown, Katherine;
Stenzel, Ashley E.;
Blaes, Anne;
Teoh, Deanna;
Vogel, Rachel I.

Publication type:

Article

The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1462

By:

Søreide, Jon Arne;
Kvaløy, Jan Terje;
Lea, Dordi;
Sandvik, Oddvar M.;
Al-Saiddi, Mohammed;
Haslerud, Torjan M.;
Garresori, Herish;
Karlsen, Lars N.;
Gudlaugsson, Einar;
Søreide, Kjetil

Publication type:

Article

Risk factors and clinical outcomes of systemic cancer treatment delays in Filipino patients with solid tumor malignancy during the COVID-19 pandemic: A single tertiary center study.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1426

By:

Pandy, Jessa Gilda;
Maaño, Omar;
Balolong-Garcia, Joanmarie C.;
Datukan, Jay T. Y.

Publication type:

Article

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1465

By:

Menon, Siddharth;
Davies, Amy;
Frentzas, Sophia;
Hawkins, Cheryl-Ann;
Segelov, Eva;
Day, Daphne;
Markman, Ben

Publication type:

Article

Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1459

By:

Leystra, Alyssa A.;
Gilsdorf, Brock J.;
Wisinger, Amanda M.;
Warda, Elise R.;
Wiegand, Shanna;
Zahm, Christopher D.;
Matkowskyj, Kristina A.;
Deming, Dustin A.;
Khan, Naghma;
Rosemarie, Quincy;
Sievers, Chelsie K.;
Schwartz, Alexander R.;
Albrecht, Dawn M.;
Clipson, Linda;
Mukhtar, Hasan;
Newton, Michael A.;
Halberg, Richard B.

Publication type:

Article

Tongue conservation treatment for oral tongue squamous cell carcinoma with induction chemotherapy, surgery, and risk-adapted adjuvant therapy: A phase II trial.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1456

By:

Tsung-Lun Lee;
Pei-Yin Wei;
Muh-Hwa Yang;
Peter Mu-Hsin Chang;
Ling-Wei Wang;
Shyh-Kuan Tai

Publication type:

Article

Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1460

By:

Rui Kitadai;
Yoshitaka Zenke;
Tsunekazu Hishima;
Yukio Hosomi

Publication type:

Article

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/ refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1476

By:

Yuka Kawaji-Kanayama;
Tsutomu Kobayashi;
Ayako Muramatsu;
Hitoji Uchiyama;
Nana Sasaki;
Nobuhiko Uoshima;
Mitsushige Nakao;
Ryoichi Takahashi;
Kazuho Shimura;
Hiroto Kaneko;
Miki Kiyota;
Katsuya Wada;
Yoshiaki Chinen;
Koichi Hirakawa;
Shin-ichi Fuchida;
Chihiro Shimazaki;
Yayoi Matsumura-Kimoto;
Shinsuke Mizutani;
Taku Tsukamoto;
Yuji Shimura

Publication type:

Article

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1471

By:

Naoki Kamachi;
Masahito Nakano;
Shusuke Okamura;
Takashi Niizeki;
Hideki Iwamoto;
Shigeo Shimose;
Tomotake Shirono;
Yu Noda;
Ryoko Kuromatsu;
Hironori Koga;
Takuji Torimura

Publication type:

Article

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1464

By:

Atsushi Hiraoka;
Takashi Kumada;
Toshifumi Tada;
Masashi Hirooka;
Kazuya Kariyama;
Joji Tani;
Masanori Atsukawa;
Koichi Takaguchi;
Ei Itobayashi;
Shinya Fukunishi;
Kunihiko Tsuji;
Toru Ishikawa;
Kazuto Tajiri;
Hironori Ochi;
Satoshi Yasuda;
Hidenori Toyoda;
Chikara Ogawa;
Takashi Nishimura;
Takeshi Hatanaka;
Hideko Ohama

Publication type:

Article

Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1467

By:

Guigay, Joël;
Chamorey, Emmanuel;
Lefebvre, Gautier;
Rotarski, Maciej;
Wagner, Jean-Philippe;
Blot, Emmanuel;
Alfonsi, Marc;
Seronde, Audrey;
Schulten, Jeltje;
Peyrade, Frédéric;
Le Tourneau, Christophe

Publication type:

Article

Cannabinoids, their cellular receptors, and effects on the invasive phenotype of carcinoma and metastasis.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1475

By:

Glogauer, Judah;
Blay, Jonathan

Publication type:

Article

Classical Hodgkin's lymphoma with cutaneous involvement in an adolescent male: A case study.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1473

By:

Ghosh, Sumon;
Ghosh, Sajib;
Amin, Rownak Jahan;
Chowdhury, Fahmida;
Prasad, Namala Satya;
Prabu, Pandurangan;
Chowdhury, Sukanta

Publication type:

Article

A retrospective analysis of discharge summaries from a tertiary care hospital medical oncology unit: To assess compliance with documentation of recommended discharge summary components.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1457

By:

Jingwei Ge;
Davis, Alison;
Jain, Ankit

Publication type:

Article

Langerhans cell histiocytosis: Presentation in a preterm neonate.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1472

By:

Alvarez, Ana Fadhel;
Patel, Shaily P.;
Brasher, Maya I.;
Ruggiero, Jaclyn E.;
Aneji, Chiamaka

Publication type:

Article

Forty-eight-year-old female MUTYH carrier presenting with five concurrent primary cancers.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1455

By:

Arroyave, Aaron;
Nodit, Laurentia;
Clegg, Devin;
Russ, Andrew

Publication type:

Article

Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1466

By:

Alshehri, Khalid;
Alqurashi, Yousuf;
Merdad, Mazin;
Samargandy, Shaza;
Daghistani, Razan;
Marzouki, Hani

Publication type:

Article

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy.

Published in:

Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1470

By:

van Aken, Evert S. M.;
Beeker, Aart;
Houtenbos, Ilse;
Pos, Floris J.;
Linn, Sabine C.;
Elkhuizen, Paula H. M.;
de Jong, Monique C.

Publication type:

Article